Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.
暂无分享,去创建一个
Ningfei Li | D. Rockey | J. Kaifi | T. Cooper | T. Schell | Guangfu Li | D. Cole | K. Staveley-O’Carroll | C. Rountree | Xiaoqiang Qi | Diego M. Avella | E. Kimchi | M. Kester | Qing-xu Yang | Dai Liu | T. Jussuf | Kaifi | -. KevinFStaveley | O'Carroll
[1] J. Prieto,et al. Immunological landscape and immunotherapy of hepatocellular carcinoma , 2015, Nature Reviews Gastroenterology &Hepatology.
[2] Guangfu Li,et al. Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma , 2015, Journal of clinical & cellular immunology.
[3] D. Morgensztern,et al. Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era? , 2015, Expert review of clinical immunology.
[4] Joon-Oh Park,et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. , 2015, The Lancet. Oncology.
[5] S. Kim,et al. Reply to "The problem of the most appropriate curative treatment for hepatocellular carcinoma. When to embolize? When to operate?". , 2015, Journal of hepatology.
[6] S. El-Etreby,et al. Guide for diagnosis and treatment of hepatocellular carcinoma. , 2015, World journal of hepatology.
[7] T. Yau,et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] X. Wang,et al. Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches , 2015, Gut.
[9] J. Marchand,et al. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice , 2014, Gut.
[10] B. Sangro,et al. Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model , 2013, Clinical Cancer Research.
[11] Michelle L. West,et al. CC chemokine receptor 8 potentiates donor Treg survival and is critical for the prevention of murine graft-versus-host disease. , 2013, Blood.
[12] P. Galle,et al. Facing the dawn of immunotherapy for hepatocellular carcinoma. , 2013, Journal of hepatology.
[13] G. Karaca,et al. Smoothened is a master regulator of adult liver repair. , 2013, The Journal of clinical investigation.
[14] E. Wagner,et al. Mouse models for liver cancer , 2013, Molecular oncology.
[15] C. Loddenkemper,et al. Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance. , 2013, The Journal of clinical investigation.
[16] John D Lambris,et al. Complement inhibition in cancer therapy. , 2013, Seminars in immunology.
[17] T. Luedde,et al. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer , 2012, Gut.
[18] S. S. Zhang,et al. Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model , 2012, Hepatology.
[19] C. Drake,et al. Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma , 2011, Clinical Cancer Research.
[20] C. Punt,et al. Cancer immunotherapy – revisited , 2011, Nature Reviews Drug Discovery.
[21] N. McDonnell,et al. Doxycycline Ameliorates the Susceptibility to Aortic Lesions in a Mouse Model for the Vascular Type of Ehlers-Danlos Syndrome , 2011, Journal of Pharmacology and Experimental Therapeutics.
[22] R. Thimme,et al. Potential of immunotherapy for hepatocellular carcinoma. , 2011, Journal of hepatology.
[23] J. Bruix,et al. Management of hepatocellular carcinoma: An update , 2011, Hepatology.
[24] S. Groshen,et al. Portable Filter-Based Microdevice for Detection and Characterization of Circulating Tumor Cells , 2010, Clinical Cancer Research.
[25] C. Nanni,et al. A novel model of CCl4-induced cirrhosis with ascites in the mouse. , 2009, Journal of hepatology.
[26] W. Pan,et al. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients , 2009, International journal of cancer.
[27] C. Divino,et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. , 2009, Cancer research.
[28] J. Bluestone,et al. Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways , 2008, Immunological reviews.
[29] P. Brossart,et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. , 2008, Blood.
[30] A. Chakraborty,et al. Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis , 2008, Nature Reviews Cancer.
[31] Siyang Zheng,et al. Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. , 2007, Journal of chromatography. A.
[32] P. Paterlini-Bréchot,et al. Circulating tumor cells (CTC) detection: clinical impact and future directions. , 2007, Cancer letters.
[33] C. Trautwein,et al. CB1 cannabinoid receptor antagonism: A new strategy for the treatment of liver fibrosis , 2007, Hepatology.
[34] T. Schell,et al. Early Immunization Induces Persistent Tumor-Infiltrating CD8+ T Cells against an Immunodominant Epitope and Promotes Lifelong Control of Pancreatic Tumor Progression in SV40 Tumor Antigen Transgenic Mice1 , 2006, The Journal of Immunology.
[35] Weiping Zou,et al. Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.
[36] S. Davies,et al. Compromised lymphocytes infiltrate hepatocellular carcinoma: The role of T‐regulatory cells , 2005, Hepatology.
[37] L. Butterfield. Immunotherapeutic strategies for hepatocellular carcinoma. , 2004, Gastroenterology.
[38] George Coukos,et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.
[39] M. J. Tevethia,et al. In Vivo Ligation of CD40 Enhances Priming Against the Endogenous Tumor Antigen and Promotes CD8+ T Cell Effector Function in SV40 T Antigen Transgenic Mice1 , 2003, The Journal of Immunology.
[40] M. Nishimura,et al. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. , 2002, Immunity.
[41] D. Gabrilovich,et al. Immature myeloid cells and cancer-associated immune suppression , 2002, Cancer Immunology, Immunotherapy.
[42] Nicholas R. English,et al. Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.
[43] Yasuo Ohashi,et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial , 2000, The Lancet.
[44] Cheryl Jorcyk,et al. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma , 2000, Oncogene.
[45] A. Ribas,et al. α-Fetoprotein-specific Genetic Immunotherapy for Hepatocellular Carcinoma , 1999 .
[46] P. Klenerman,et al. Immune surveillance against a solid tumor fails because of immunological ignorance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[47] F. Chisari,et al. Immune Pathogenesis of Hepatocellular Carcinoma , 1998, The Journal of experimental medicine.
[48] M. Kojiro,et al. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration , 1998, Hepatology.
[49] J. Green,et al. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[50] J. Mullins,et al. T antigen expression and tumorigenesis in transgenic mice containing a mouse major urinary protein/SV40 T antigen hybrid gene. , 1989, The EMBO journal.
[51] E. Farber. The multistep nature of cancer development. , 1984, Cancer research.
[52] G. L. Levi Sandri,et al. The problem of the most appropriate curative treatment for hepatocellular carcinoma. When to embolize? When to operate? , 2015, Journal of hepatology.
[53] Riccardo Lencioni,et al. Design and endpoints of clinical trials in hepatocellular carcinoma. , 2008, Journal of the National Cancer Institute.
[54] A. Ribas,et al. Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. , 1999, Cancer research.